Therefore, deep sequencing dozens to hundreds of cancer-related genes have to be carefully evaluated to determine if the benefits outweigh the disadvantages, especially for PDAC, where at least one of a few KRAS variants are observed in most cases. This evidence concerns the gene KRAS and cancer.